(Cambridge
UK, April 10, 2002) RiboTargets,
a structure-based drug discovery company that develops novel
anti-infective and anti-cancer therapeutics, announces that work has begun
on doubling the capacity of its corporate headquarters on Granta Park,
Cambridge.
Having
outgrown its existing 25,000 sq.ft of purpose built offices and
laboratories, RiboTargets has exercised the right to an adjacent plot of
land allowing major expansion without relocation.
The new building, with a capacity of 30,000 sq ft, is due for
completion in September 2003. It
will be joined to the original facility and has been designed to
accommodate expansion of RiboTargets’ chemical and biology laboratories
RiboTargets,
the first tenant on the 84-acre research park, took residency in October
1999 and have since been joined by some of the industry’s leading
companies, including Millennium Pharmaceuticals, Cambridge Antibody
Technology and Celltech R&D.
RiboTargets’ CEO, Simon Sturge commented, “This
substantial expansion to our facility will accommodate the company's
growth for the foreseeable future”.
Copy
Ends
For
an electronic image of the existing RiboTargets building with the new site
in the foreground, please contact STMP Marketing Solutions Ltd
For more information, please contact
Susan
Lowther
Finance Director
RiboTargets Ltd
Granta Park, Cambridge, CB1 6GB, UK
Tel: +44 (0)1223 895555 Fax: +44 (0)1223 895355
s.lowther@ribotargets.com
James
Parkinson
STMP Marketing Solutions Ltd
Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK
Tel: +44 (0)1260 296500 Fax: +44 (0)1260 296501
james@stmpmarketing.com
Notes to Editors
About RiboTargets Ltd
RiboTargets
is a privately owned pharmaceutical drug discovery company focused on the
development of novel anti-infective and anti-cancer therapeutics.
These therapeutic areas represent significant market opportunities.
The
Company has created and validated a proprietary structure-based drug
discovery engine that allows the rapid identification and optimisation of
drug candidates against both protein and nucleic acid targets using high
throughput computer-aided and experimental drug design.
Over
the last four years, RiboTargets has made the transition from a technology
platform company into a competitive drug discovery company.
RiboTargets’ goal for 2002 is to make the pivotal step from
research into formal drug development.
In the longer term, RiboTargets aims to become a significant player
in the anti-infective and anti-cancer markets.
Website: www.ribotargets.com
